MedTrace Logo

Use of Quetiapine as an Add on Therapy in the Treatment of Post Traumatic Stress Disorder

NCT00306540 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2010-12-09

No results posted yet for this study

Summary

The purpose of this study is to evaluate how effective quetiapine versus placebo is when added to an existing therapy, in reducing the symptoms of PTSD.

Conditions

  • Post-Traumatic Stress Disorder

Interventions

DRUG

Quetiapine Fumarate

oral flexible dose

DRUG

quetiapine fumarate placebo

oral 0 mg

Sponsors & Collaborators

Principal Investigators

  • AstraZeneca Australia Medical Director, MD · AstraZeneca

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-12-31
Primary Completion
2007-09-30
Completion
2008-08-31

Countries

  • Australia

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00306540 on ClinicalTrials.gov